<DOC>
	<DOCNO>NCT00428974</DOCNO>
	<brief_summary>This study test hypothesis CF101 , development treat immune-mediated inflammatory disease , provide clinical benefit treatment chronic plaque psoriasis . Patients psoriasis qualify study treat every 12 hour ( q12h ) CF101 capsule , placebo capsule , 12 week . The safety treatment carefully assess clinical laboratory monitoring . The effect treatment psoriasis evaluate standard technique examination measurement severity skin involvement .</brief_summary>
	<brief_title>Safety Efficacy Study CF101 Treat Psoriasis</brief_title>
	<detailed_description>This Phase 2 , multicenter , randomize , double-blind , dose-ranging , placebo-controlled , study adult male female , age 18 70 year , inclusive , diagnosis moderate-to-severe chronic plaque psoriasis . At Screening Visit , patient provide write informed consent screening procedure perform , include complete medical history , medication history , physical examination , include height , weight , blood pressure , pulse rate temperature , clinical laboratory test . Eligible patient receive systemic retinoids , corticosteroid , immunosuppressant ( e.g. , methotrexate , cyclosporine ) within 6 week prior initiation study ; high potency topical corticosteroid ( Class I-III ) , keratolytics , coal tar ( scalp , palm , groin , and/or sol ) ; UV Dead Sea therapy within 4 week prior initiation study treatment . Eligible patient sequentially assign 1 3 dosing cohort : Cohort 1 : CF101 1 mg ( 15 patient ) Placebo ( 5 patient ) ; Cohort 2 : CF101 2 mg ( 15 patient ) Placebo ( 5 patient ) ; Cohort 3 : CF101 4 mg ( 15 patient ) Placebo ( 5 patient ) . Medication take orally q12h 12 week . Disease activity assess use Psoriasis Area Severity Index ( PASI ) Physician Global Assessment ( PGA ) . Patients return assessment Weeks 2 , 4 , 8 , 12 14 .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<criteria>Male female , 18 70 year age , inclusive ; Diagnosis moderatetosevere chronic plaquetype psoriasis body surface area involvement ≥10 % , judge Investigator ; Duration psoriasis least 6 month ; PASI score ≥10 ; Body weight ≤100 kg ; Candidate systemic treatment phototherapy psoriasis ; ECG normal show abnormality , judgment Investigator , clinically significant ; Females childbearing potential must negative serum pregnancy test screening ; Females childbearing potential must willing use 2 method contraception deem adequate Investigator ( example oral contraceptive pill plus barrier method ) eligible , continue participation , study ; Ability complete study compliance protocol ; Ability understand provide write informed consent . Erythrodermic , guttate , palmar , plantar , generalize pustular psoriasis ; Treatment systemic retinoids , corticosteroid , immunosuppressant ( e.g. , methotrexate , cyclosporine ) within 6 week Baseline visit ; Treatment high potency topical corticosteroid ( Class IIII ) , keratolytics , coal tar ( scalp , palm , groin , and/or sol ) within 2 week Baseline visit ; Ultraviolet Dead Sea therapy within 4 week Baseline visit , anticipate need either therapy study period ; Treatment biological agent ( include etanercept , adalimumab , efalizumab , infliximab , alefacept ) within period time equal 5 time circulate halflife , 30 day , whichever longer , prior Baseline visit ; History poor clinical response methotrexate adequate regimen duration treatment ; Treatment systemic nonsteroidal antiinflammatory drug , betablockers , lithium , hydroxychloroquine , chloroquine , systemic terbinafine within 2 week Baseline visit , anticipate need drug study period ; Presence history uncontrolled asthma ; Presence history uncontrolled arterial hypertension symptomatic hypotension ; Significant cardiac arrhythmia conduction block , congestive heart failure ( New York Heart Association Class 34 ) , evidence clinically significant heart disease clinically significant finding screen electrocardiogram ; Hemoglobin level &lt; 9.0 gm/L ; Platelet count &lt; 125,000/mm^3 ; White blood cell count &lt; 3500/mm^3 ; Serum creatinine level great 1.5 time laboratory 's upper limit normal ; Liver aminotransferase level great 2 time laboratory 's upper limit normal ; Pregnancy , plan pregnancy , lactation , inadequate contraception judge Investigator ; History malignancy within past 5 year ( exclude basal cell carcinoma skin ≤3 cutaneous squamous cell carcinoma , completely excise ) ; Significant acute chronic medical psychiatric illness , judgment Investigator , could compromise patient safety , limit patient 's ability complete study , and/or compromise objective study ; Participation another investigational drug vaccine trial concurrently within 30 day ; within 5 half life biological investigational product , whichever longer ; Other condition would confound study evaluation endanger safety patient .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>Psoriasis</keyword>
</DOC>